In a filing, Y-Mabs Therapeutics Inc revealed its CHIEF BUSINESS OFFICER Gad Thomas unloaded Company’s shares for reported $0.88 million on Sep 13 ’24. In the deal valued at $13.47 per share,65,000 shares were sold. As a result of this transaction, Gad Thomas now holds 97,681 shares worth roughly $1.09 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Gad Thomas sold 30,000 shares, generating $389,100 in total proceeds. Upon selling the shares at $12.97, the CHIEF BUSINESS OFFICER now owns 67,681 shares.
Before that, Thomas Gad bought 100,000 shares. Y-Mabs Therapeutics Inc shares valued at $1,374,000 were divested by the Officer at a price of $13.74 per share.
Cantor Fitzgerald initiated its Y-Mabs Therapeutics Inc [YMAB] rating to an Overweight in a research note published on August 16, 2024; the price target was $20. A number of analysts have revised their coverage, including Truist’s analysts, who began to cover the stock in late June with a ‘”a Buy”‘ rating. Wedbush also remained covering YMAB and has increased its forecast on May 10, 2023 with a “an Outperform” recommendation from previously “Neutral” rating. Guggenheim revised its rating on April 03, 2023. It rated YMAB as “a Neutral” which previously was an “a Buy”.
Price Performance Review of YMAB
On Friday, Y-Mabs Therapeutics Inc [NASDAQ:YMAB] saw its stock fall -3.88% to $11.14. Over the last five days, the stock has lost -28.04%. Y-Mabs Therapeutics Inc shares have risen nearly 63.34% since the year began. Nevertheless, the stocks have risen 112.19% over the past one year. While a 52-week high of $20.90 was reached on 03/01/24, a 52-week low of $5.04 was recorded on 01/03/24. SMA at 50 days reached $13.98, while 200 days put it at $13.81.
Levels Of Support And Resistance For YMAB Stock
The 24-hour chart illustrates a support level at 10.60, which if violated will result in even more drops to 10.06. On the upside, there is a resistance level at 11.67. A further resistance level may holdings at 12.19. The Relative Strength Index (RSI) on the 14-day chart is 25.01, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.28, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.04%. Stochastics %K at 10.51% indicates the stock is a buying.
How much short interest is there in Y-Mabs Therapeutics Inc?
A steep rise in short interest was recorded in Y-Mabs Therapeutics Inc stocks on 2024-10-31, dropping by -0.16 million shares to a total of 4.01 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 4.17 million shares. There was a decline of -3.91%, which implies that there is a negative sentiment for the stock.
